Poster: SIERRAS: A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in Subjects with ESRD on Stable Dialysis
Authors: Chaim Charytan, MD, Nephrology Associates, PC, New Rochelle, New York, et al
Roxadustat (ROXA) is an oral hypoxia–inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. And the drug — a novel first-in-class treatment for certain people with anemia from chronic kidney disease (CKD) — is being closely watched as its Phase III program pooled analyses continue to prompt headline-worthy news. In short, ROXA shows positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease.
Specific to the SIERRAS trial, showcased in a larger-than-life poster presentation on Saturday morning, ROXA was non-inferior and subsequently demonstrated superiority over epoetin alfa in dialysis-dedicated patients (click here for poster).
The crowd around the SIERRAS poster was dense — and if able to get close enough, the CONCLUSION explained some of the many reasons why everyone’s watching ROXA. Here’s an abbreviated review of SIERRAS’ conclusions.